U.S. Markets open in 4 hrs 27 mins

Why Cortexyme Thinks It Could Be Next In The Mega Alzheimer's Drug Market

·3 min read
Why Cortexyme Thinks It Could Be Next In The Mega Alzheimer's Drug Market
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

The next donnybrook in Alzheimer's disease is looming. Biogen gained the first approval, and a slew of biotech stocks are now lining up.